Drug treatment of cancer cell lines: A way to select for cancer stem cells?

Cancers

Volumn 3, Issue 1, 2011, Pages 1111-1128

  Chiodi, Ilaria ^a   Belgiovine, Cristina ^a   Donà, Francesca ^a   Scovassi, A Ivana ^a   Mondello, Chiara ^a  

^a CNR   (Italy)

Author keywords

Cancer; Chemotherapy; Drug resistance; Stem cells

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BREAST CANCER RESISTANCE PROTEIN; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; FLUOROURACIL; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; TEMOZOLOMIDE; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CELL DEDIFFERENTIATION; CELL ISOLATION; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; CELL SELECTION; DRUG TARGETING; ENRICHMENT CULTURE; EPITHELIAL MESENCHYMAL TRANSITION; GLIOMA; HUMAN; NONHUMAN; OVARY CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW;

EID: 79953725145     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3011111     Document Type: Review

References (109)

1. Reya, T.; Morrison, S.J.; Clarke, M.F.; Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414, 105-111.
2. Lapidot, T.; Sirard, C.; Vormoor, J.; Murdoch, B.; Hoang, T.; Caceres-Cortes, J.; Minden, M.; Paterson, B.; Caligiuri, M.A.; Dick, J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367, 645-648.
3. Bonnet, D.; Dick, J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3, 730-737.
4. Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 3983-3988.
5. Hermann, P.C.; Bhaskar, S.; Cioffi, M.; Heeschen, C. Cancer stem cells in solid tumors. Semin. Cancer Biol. 2010, 20, 77-84.
6. Quintana, E.; Shackleton, M.; Sabel, M.S.; Fullen, D.R.; Johnson, T.M.; Morrison, S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456, 593-598.
7. Chiou, S.H.; Yu, C.C.; Huang, C.Y.; Lin, S.C.; Liu, C.J.; Tsai, T.H.; Chou, S.H.; Chien, C.S.; Ku, H.H.; Lo, J.F. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin. Cancer. Res. 2008, 14, 4085-4095.
8. Harris, M.A.; Yang, H.; Low, B.E.; Mukherjee, J.; Guha, A.; Bronson, R.T.; Shultz, L.D.; Israel, M.A.; Yun, K. Cancer stem cells are enriched in the side population cells in a mouse model of glioma. Cancer Res. 2008, 68, 10051-10059.
9. Thon, N.; Damianoff, K.; Hegermann, J.; Grau, S.; Krebs, B.; Schnell, O.; Tonn, J.C.; Goldbrunner, R. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas. Mol. Cell. Neurosci. 2010, 43, 51-59.
10. Maenhaut, C.; Dumont, J.E.; Roger, P.P.; van Staveren, W.C. Cancer stem cells: a reality, a myth, a fuzzy concept or a misnomer? An analysis. Carcinogenesis 2010, 31, 149-158.
11. Ginestier, C.; Hur, M.H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C.G.; Liu, S.; et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1, 555-567.
12. Hirschmann-Jax, C.; Foster, A.E.; Wulf, G.G.; Nuchtern, J.G.; Jax, T.W.; Gobel, U.; Goodell, M.A.; Brenner, M.K. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA 2004, 101, 14228-14233.
13. Haraguchi, N.; Utsunomiya, T.; Inoue, H.; Tanaka, F.; Mimori, K.; Barnard, G.F.; Mori, M. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006, 24, 506-513.
14. Ho, M.M.; Ng, A.V.; Lam, S.; Hung, J.Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007, 67, 4827-4833.
15. Zhang, P.; Zhang, Y.; Mao, L.; Zhang, Z.; Chen, W. Side population in oral squamous cell carcinoma possesses tumor stem cell phenotypes. Cancer Lett. 2009, 277, 227-234.
16. Schinkel, A.H.; Jonker, J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 2003, 55, 3-29.
17. Ding, X.W.; Wu, J.H.; Jiang, C.P. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci. 2010, 86, 631-637.
18. Zhou, B.B.; Zhang, H.; Damelin, M.; Geles, K.G.; Grindley, J.C.; Dirks, P.B. Tumour-initiating cells: Challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 2009, 8, 806-823.
19. Baumann, M.; Krause, M.; Thames, H.; Trott, K.; Zips, D. Cancer stem cells and radiotherapy. Int. J. Radiat. Biol. 2009, 85, 391-402.
20. Sengupta, A.; Cancelas, J.A. Cancer stem cells: a stride towards cancer cure? J. Cell. Physiol. 2010, 225, 7-14.
21. Reynolds, B.A.; Weiss, S. Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev. Biol. 1996, 175, 1-13.
22. Weiss, S.; Dunne, C.; Hewson, J.; Wohl, C.; Wheatley, M.; Peterson, A.C.; Reynolds, B.A. Multipotent CNS stem cells are present in the adult mammalian spinal cord and ventricular neuroaxis. J. Neurosci. 1996, 16, 7599-7609.
23. Dontu, G.; Abdallah, W.M.; Foley, J.M.; Jackson, K.W.; Clarke, M.F.; Kawamura, M.J.; Wicha, M.S. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003, 17, 1253-1270.
24. Singh, S.K.; Clarke, I.D.; Terasaki, M.; Bonn, V.E.; Hawkins, C.; Squire, J.; Dirks, P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63, 5821-5828.
25. Singh, S.K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T.; Henkelman, R.M.; Cusimano, M.D.; Dirks, P.B. Identification of human brain tumour initiating cells. Nature 2004, 432, 396-401.
26. Galli, R.; Binda, E.; Orfanelli, U.; Cipelletti, B.; Gritti, A.; De Vitis, S.; Fiocco, R.; Foroni, C.; Dimeco, F.; Vescovi, A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004, 64, 7011-7021.
27. Yuan, X.; Curtin, J.; Xiong, Y.; Liu, G.; Waschsmann-Hogiu, S.; Farkas, D.L.; Black, K.L.; Yu, J.S. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004, 23, 9392-9400.
28. Fang, D.; Nguyen, T.K.; Leishear, K.; Finko, R.; Kulp, A.N.; Hotz, S.; Van Belle, P.A.; Xu, X.; Elder, D.E.; Herlyn, M. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005, 65, 9328-9337.
29. Ponti, D.; Costa, A.; Zaffaroni, N.; Pratesi, G.; Petrangolini, G.; Coradini, D.; Pilotti, S.; Pierotti, M.A.; Daidone, M.G. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005, 65, 5506-5511.
30. Phillips, T.M.; McBride, W.H.; Pajonk, F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J. Nat. Cancer Inst. 2006, 98, 1777-1785.
31. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126, 663-676.
32. Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131, 861-872.
33. Bass, A.J.; Watanabe, H.; Mermel, C.H.; Yu, S.; Perner, S.; Verhaak, R.G.; Kim, S.Y.; Wardwell, L.; Tamayo, P.; Gat-Viks, I.; et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat. Genet. 2009, 41, 1238-1242.
34. Banito, A.; Rashid, S.T.; Acosta, J.C.; Li, S.; Pereira, C.F.; Geti, I.; Pinho, S.; Silva, J.C.; Azuara, V.; Walsh, M.; Vallier, L.; Gil, J. Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev. 2009, 23, 2134-2139.
35. Utikal, J.; Polo, J.M.; Stadtfeld, M.; Maherali, N.; Kulalert, W.; Walsh, R.M.; Khalil, A.; Rheinwald, J.G.; Hochedlinger, K. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 2009, 460, 1145-1148.
36. Huntly, B.J.; Shigematsu, H.; Deguchi, K.; Lee, B.H.; Mizuno, S.; Duclos, N.; Rowan, R.; Amaral, S.; Curley, D.; Williams, I.R.; Akashi, K.; Gilliland, D.G. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004, 6, 587-596.
37. Krivtsov, A.V.; Twomey, D.; Feng, Z.; Stubbs, M.C.; Wang, Y.; Faber, J.; Levine, J.E.; Wang, J.; Hahn, W.C.; Gilliland, D.G.; Golub, T.R.; Armstrong, S.A. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442, 818-822.
38. Morel, A.P.; Lievre, M.; Thomas, C.; Hinkal, G.; Ansieau, S.; Puisieux, A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008, 3, e2888.
39. Zongaro, S.; de Stanchina, E.; Colombo, T.; D'Incalci, M.; Giulotto, E.; Mondello, C. Stepwise neoplastic transformation of a telomerase immortalized fibroblast cell line. Cancer Res. 2005, 65, 11411-11418.
40. Boehm, J.S.; Hahn, W.C. Understanding transformation: progress and gaps. Curr. Opin. Genet. Dev. 2005, 15, 13-17.
41. Polyak, K.; Weinberg, R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9, 265-273.
42. Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M.; Campbell, L.L.; Polyak, K.; Brisken, C.; Yang, J.; Weinberg, R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704-715.
43. Gupta, P.B.; Chaffer, C.L.; Weinberg, R.A. Cancer stem cells: mirage or reality? Nat. Med. 2009, 15, 1010-1012.
44. Al-Hajj, M.; Becker, M.W.; Wicha, M.; Weissman, I.; Clarke, M.F. Therapeutic implications of cancer stem cells. Curr. Opin. Genet. Dev. 2004, 14, 43-47.
45. Greaves, M. Cancer stem cells: back to Darwin? Semin. Cancer Biol. 2010, 20, 65-70.
46. Jordan, C.T. Cancer stem cells: Controversial or just misunderstood? Cell Stem Cell 2009, 4, 203-205.
47. Masters, J.R. Human cancer cell lines: fact and fantasy. Nat. Rev. Mol. Cell. Biol. 2000, 1, 233-236.
48. van Staveren, W.C.; Solis, D.Y.; Hebrant, A.; Detours, V.; Dumont, J.E.; Maenhaut, C. Human cancer cell lines: Experimental models for cancer cells in situ? For cancer stem cells? Biochim. Biophys. Acta 2009, 1795, 92-103.
49. Kondo, T.; Setoguchi, T.; Taga, T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc. Natl. Acad. Sci. USA 2004, 101, 781-786.
50. Lee, J.; Kotliarova, S.; Kotliarov, Y.; Li, A.; Su, Q.; Donin, N.M.; Pastorino, S.; Purow, B.W.; Christopher, N.; Zhang, W.; Park, J.K.; Fine, H.A. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9, 391-403.
51. Yu, F.; Yao, H.; Zhu, P.; Zhang, X.; Pan, Q.; Gong, C.; Huang, Y.; Hu, X.; Su, F.; Lieberman, J.; Song, E. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131, 1109-1123.
52. Christgen, M.; Ballmaier, M.; Bruchhardt, H.; von Wasielewski, R.; Kreipe, H.; Lehmann, U. Identification of a distinct side population of cancer cells in the Cal-51 human breast carcinoma cell line. Mol. Cell. Biochem. 2007, 306, 201-212.
53. Kasper, S. Identification, characterization, and biological relevance of prostate cancer stem cells from clinical specimens. Urol. Oncol. 2009, 27, 301-303.
54. Gasparini, P.; Bertolini, G.; Binda, M.; Magnifico, A.; Albano, L.; Tortoreto, M.; Pratesi, G.; Facchinetti, F.; Abolafio, G.; Roz, L.; Tagliabue, E.; Daidone, M.G.; Sozzi, G. Molecular cytogenetic characterization of stem-like cancer cells isolated from established cell lines. Cancer Lett. 2010, 296, 206-215.
55. Honoki, K.; Fujii, H.; Kubo, A.; Kido, A.; Mori, T.; Tanaka, Y.; Tsujiuchi, T. Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol. Rep. 2010, 24, 501-505.
56. Li, G.; Liu, C.; Yuan, J.; Xiao, X.; Tang, N.; Hao, J.; Wang, H.; Bian, X.; Deng, Y.; Ding, Y. CD1 33(+) single cell-derived progenies of colorectal cancer cell line SW480 with different invasive and metastatic potential. Clin. Exp. Metastas. 2010, 27, 517-527.
57. Louie, E.; Nik, S.; Chen, J.S.; Schmidt, M.; Song, B.; Pacson, C.; Chen, X.F.; Park, S.; Ju, J.; Chen, E.I. Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res. 2010, 12, R94.
58. Newton, T.C.; Wolcott, K.; Roberts, S.S. Comparison of the side populations in pretreatment and postrelapse neuroblastoma cell lines. Transl. Oncol. 2010, 3, 246-251.
59. Perego, M.; Tortoreto, M.; Tragni, G.; Mariani, L.; Deho, P.; Carbone, A.; Santinami, M.; Patuzzo, R.; Mina, P.D.; Villa, A.; Pratesi, G.; Cossa, G.; Perego, P.; Daidone, M.G.; Alison, M.R.; Parmiani, G.; Rivoltini, L.; Castelli, C. Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells. J. Invest. Dermatol. 2010, 130, 1877-1886.
60. Sajithlal, G.B.; Rothermund, K.; Zhang, F.; Dabbs, D.J.; Latimer, J.J.; Grant, S.G.; Prochownik, E.V. Permanently blocked stem cells derived from breast cancer cell lines. Stem Cells 2010, 28, 1008-1018.
61. Shi, M.F.; Jiao, J.; Lu, W.G.; Ye, F.; Ma, D.; Dong, Q.G.; Xie, X. Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line. Cell. Mol. Life Sci. 2010, 67, 3915-3925.
62. Yeung, T.M.; Gandhi, S.C.; Wilding, J.L.; Muschel, R.; Bodmer, W.F. Cancer stem cells from colorectal cancer-derived cell lines. Proc. Natl. Acad. Sci. USA 2010, 107, 3722-3727.
63. Zhong, Y.; Guan, K.; Guo, S.; Zhou, C.; Wang, D.; Ma, W.; Zhang, Y.; Li, C.; Zhang, S. Spheres derived from the human SK-RC-42 renal cell carcinoma cell line are enriched in cancer stem cells. Cancer Lett. 2010, 299, 150-160.
64. Wang, L.; Park, P.; Lin, C.Y. Characterization of stem cell attributes in human osteosarcoma cell lines. Cancer Biol. Ther. 2009, 8, 543-552.
65. Yang, M.; Zhang, R.; Yan, M.; Ye, Z.; Liang, W.; Luo, Z. Detection and characterization of side population in Ewing's sarcoma SK-ES-1 cells in vitro. Biochem. Biophys. Res. Commun. 2010, 391, 1062-1066.
66. Zhang, L.; Yang, S.; He, Y.J.; Shao, H.Y.; Wang, L.; Chen, H.; Gao, Y.J.; Qing, F.X.; Chen, X.C.; Zhao, L.Y.; Tan, S. Fluorouracil selectively enriches stem-like leukemic cells in a leukemic cell line. Int. J. Biol. Sci. 2010, 6, 419-427.
67. Bunting, K.D. ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 2002, 20, 11-20.
68. Calcagno, A.M.; Salcido, C.D.; Gillet, J.P.; Wu, C.P.; Fostel, J.M.; Mumau, M.D.; Gottesman, M.M.; Varticovski, L.; Ambudkar, S.V. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J. Nat. Cancer Inst. 2010, 102, 1637-1652.
69. Hirata, N.; Sekino, Y.; Kanda, Y. Nicotine increases cancer stem cell population in MCF-7 cells. Biochem. Biophys. Res. Commun. 2010, 403, 138-143.
70. Stylianou, S.; Clarke, R.B.; Brennan, K. Aberrant activation of notch signaling in human breast cancer. Cancer Res. 2006, 66, 1517-1525.
71. Slamon, D.J.; Clark, G.M.; Wong, S.G.; Levin, W.J.; Ullrich, A.; McGuire, W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177-182.
72. Slamon, D.J.; Godolphin, W.; Jones, L.A.; Holt, J.A.; Wong, S.G.; Keith, D.E.; Levin, W.J.; Stuart, S.G.; Udove, J.; Ullrich, A.; et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707-712.
73. Shak, S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpres sing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin. Oncol. 1999, 26, 71-77.
74. Tokuda, Y.; Suzuki, Y.; Saito, Y.; Umemura, S. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review. Breast Cancer 2009, 16, 295-300.
75. Kruser, T.J.; Wheeler, D.L. Mechanisms of resistance to HER family targeting antibodies. Exp. Cell Res. 2010, 316, 1083-1100.
76. Lin, S.X.; Chen, J.; Mazumdar, M.; Poirier, D.; Wang, C.; Azzi, A.; Zhou, M. Molecular therapy of breast cancer: progress and future directions. Nat. Rev. Endocrinol. 2010, 6, 485-493.
77. Ross, J.S. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. Drug News Perspect. 2009, 22, 93-106.
78. Tagliabue, E.; Balsari, A.; Campiglio, M.; Pupa, S.M. HER2 as a target for breast cancer therapy. Exp. Opin. Biol. Ther. 2010, 10, 711-724.
79. Reim, F.; Dombrowski, Y.; Ritter, C.; Buttmann, M.; Hausler, S.; Ossadnik, M.; Krockenberger, M.; Beier, D.; Beier, C.P.; Dietl, J.; Becker, J.C.; Honig, A.; Wischhusen, J. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res. 2009, 69, 8058-8066.
80. Magnifico, A.; Albano, L.; Campaner, S.; Delia, D.; Castiglioni, F.; Gasparini, P.; Sozzi, G.; Fontanella, E.; Menard, S.; Tagliabue, E. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin. Cancer Res. 2009, 15, 2010-2021.
81. Ma, L.; Lai, D.; Liu, T.; Cheng, W.; Guo, L. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Acta Biochim. Biophys. Sin. (Shanghai) 2010, 42, 593-602.
82. Bapat, S.A. Human ovarian cancer stem cells. Reproduction 2010, 140, 33-41.
83. Achanzar, W.E.; Brambila, E.M.; Diwan, B.A.; Webber, M.M.; Waalkes, M.P. Inorganic arseniteinduced malignant transformation of human prostate epithelial cells. J. Nat. Cancer Inst. 2002, 94, 1888-1891.
84. Benbrahim-Tallaa, L.; Waalkes, M.P. Inorganic arsenic and human prostate cancer. Environ. Health Perspect. 2008, 116, 158-164.
85. Tokar, E.J.; Qu, W.; Liu, J.; Liu, W.; Webber, M.M.; Phang, J.M.; Waalkes, M.P. Arsenic-specific stem cell selection during malignant transformation. J. Nat. Cancer Inst. 2010, 102, 638-649.
86. Levina, V.; Marrangoni, A.M.; DeMarco, R.; Gorelik, E.; Lokshin, A.E. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 2008, 3, e3077.
87. Charafe-Jauffret, E.; Ginestier, C.; Iovino, F.; Wicinski, J.; Cervera, N.; Finetti, P.; Hur, M.H.; Diebel, M.E.; Monville, F.; Dutcher, J.; et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009, 69, 1302-1313.
88. Ginestier, C.; Liu, S.; Diebel, M.E.; Korkaya, H.; Luo, M.; Brown, M.; Wicinski, J.; Cabaud, O.; Charafe-Jauffret, E.; Birnbaum, D.; Guan, J.L.; Dontu, G.; Wicha, M.S. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest. 2010, 120, 485-497.
89. Villano, J.L.; Seery, T.E.; Bressler, L.R. Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother. Pharmacol. 2009, 64, 647-655.
90. Chua, C.; Zaiden, N.; Chong, K.H.; See, S.J.; Wong, M.C.; Ang, B.T.; Tang, C. Characterization of a side population of astrocytoma cells in response to temozolomide. J. Neurosurg. 2008, 109, 856-866.
91. Kaneko, Y.; Sakakibara, S.; Imai, T.; Suzuki, A.; Nakamura, Y.; Sawamoto, K.; Ogawa, Y.; Toyama, Y.; Miyata, T.; Okano, H. Musashi1: An evolutionally conserved marker for CNS progenitor cells including neural stem cells. Dev. Neurosci. 2000, 22, 139-153.
92. Jin, F.; Zhao, L.; Guo, Y.J.; Zhao, W.J.; Zhang, H.; Wang, H.T.; Shao, T.; Zhang, S.L.; Wei, Y.J.; Feng, J.; Jiang, X.B.; Zhao, H.Y. Influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD1 33 positive U25 1 glioblastoma stem-like cells. Brain Res. 2010, 1336, 103-111.
93. Giansanti, V.; Donà, F.; Tillhon, M.; Scovassi, A.I. PARP inhibitors: new tools to protect from inflammation. Biochem. Pharmacol. 2010, 80, 1869-1877.
94. Megnin-Chanet, F.; Bollet, M.A.; Hall, J. Targeting poly(ADP-ribose) polymerase activity for cancer therapy. Cell. Mol. Life Sci. 2010, 67, 3649-3662.
95. Rouleau, M.; Patel, A.; Hendzel, M.J.; Kaufmann, S.H.; Poirier, G.G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 2010, 10, 293-301.
96. Villanueva, T. Expanding the horizons of PARP inhibitors. Nat. Rev. Cancer 2010, 10, 814.
97. Drew, Y.; Plummer, R. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist. Updat. 2009, 12, 153-156.
98. Patel, A.; Kaufmann, S.H. Development of PARP inhibitors: an unfinished story. Oncology (Williston Park) 2010, 24, 66-68.
99. Di Fiore, R.; Santulli, A.; Ferrante, R.D.; Giuliano, M.; De Blasio, A.; Messina, C.; Pirozzi, G.; Tirino, V.; Tesoriere, G.; Vento, R. Identification and expansion of human osteosarcoma-cancerstem cells by long-term 3-aminobenzamide treatment. J. Cell. Physiol. 2009, 219, 301-313.
100. Liu, E.H.; Qi, L.W.; Wu, Q.; Peng, Y.B.; Li, P. Anticancer agents derived from natural products. Mini Rev. Med. Chem. 2009, 9, 1547-1555.
101. Subramaniam, D.; Ramalingam, S.; Houchen, C.W.; Anant, S. Cancer stem cells: a novel paradigm for cancer prevention and treatment. Mini Rev. Med. Chem. 2010, 10, 359-371.
102. Epstein, J.; Sanderson, I.R.; Macdonald, T.T. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br. J. Nutr. 2010, 103, 1545-1557.
103. Fong, D.; Yeh, A.; Naftalovich, R.; Choi, T.H.; Chan, M.M. Curcumin inhibits the side population (SP) phenotype of the rat C6 glioma cell line: towards targeting of cancer stem cells with phytochemicals. Cancer Lett. 2010, 293, 65-72.
104. Guzman, M.L.; Rossi, R.M.; Karnischky, L.; Li, X.; Peterson, D.R.; Howard, D.S.; Jordan, C.T. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005, 105, 4163-4169.
105. Zhou, J.; Zhang, H.; Gu, P.; Bai, J.; Margolick, J.B.; Zhang, Y. NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res. Treat. 2008, 111, 419-427.
106. Kim, J.B.; Ko, E.; Han, W.; Shin, I.; Park, S.Y.; Noh, D.Y. Berberine diminishes the side population and ABCG2 transporter expression in MCF-7 breast cancer cells. Planta Med. 2008, 74, 1693-1700.
107. Bar, E.E.; Chaudhry, A.; Lin, A.; Fan, X.; Schreck, K.; Matsui, W.; Piccirillo, S.; Vescovi, A.L.; DiMeco, F.; Olivi, A.; Eberhart, C.G. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 2007, 25, 2524-2533.
108. Hirsch, H.H.; Iliopoulus, D.; Tsichlis, P.N.; Struhl, K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009, 69, 7507-7511.
109. Martin-Castillo, B.; Vazquez-Martin, A.; Oliveras-Ferraros, C.; Menendez, J.A. Metformin and cancer. Cell Cycle 2010, 9, 1057-1064.